Eliem Therapeutics (ELYM) Stock Chart & Stock Price History $1.48 +0.07 (+4.96%) As of 07/23/2025 Add Compare Share Share Chart Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Eliem Therapeutics Stock Price Performance The Eliem Therapeutics (ELYM) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 82.93%, with a year-to-date return of -20.00%. In the past month, the stock has increased 23.33%, reflecting recent market activity. As of the latest close, Eliem Therapeutics traded at $1.41 with a market cap of $41.95 million and volume of 64,961 shares. Receive ELYM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+1.37%1 Month Performance+23.33%3 Month Performance+10.45%Year-To-Date Performance-20.00%1 Year Performance-82.93% ELYM Stock Chart for Thursday, July, 24, 2025 ELYM Chart by TradingView Eliem Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/23/2025$1.51$1.41-6.62%$1.44$1.3764,961 shs$41.95 million07/22/2025$1.51$1.51$1.55$1.45159,187 shs$44.93 million07/21/2025$1.51$1.51$1.55$1.45159,187 shs$44.93 million07/18/2025$1.40$1.46+4.29%$1.51$1.40238,236 shs$43.44 million07/17/2025$1.37$1.40+2.19%$1.43$1.37190,980 shs$41.65 million07/16/2025$1.42$1.37-3.52%$1.42$1.3582,472 shs$40.76 million07/15/2025$1.37$1.42+3.65%$1.45$1.35165,418 shs$42.25 million07/14/2025$1.37$1.37$1.39$1.32246,292 shs$40.76 million07/11/2025$1.35$1.35$1.37$1.25594,315 shs$40.17 million07/10/2025$1.28$1.35+5.47%$1.37$1.25594,315 shs$40.17 million Get the Latest News and Ratings for ELYM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/09/2025$1.28$1.28$1.32$1.24158,764 shs$38.08 million07/08/2025$1.28$1.28$1.32$1.24158,764 shs$38.08 million07/07/2025$1.28$1.28$1.32$1.24158,764 shs$38.08 million07/04/2025$1.26$1.28+1.59%$1.32$1.24158,764 shs$38.08 million07/03/2025$1.19$1.26+5.88%$1.28$1.19182,228 shs$37.49 million07/02/2025$1.24$1.19-4.03%$1.25$1.19215,669 shs$35.41 million07/01/2025$1.18$1.24+5.08%$1.25$1.20186,214 shs$36.89 million06/30/2025$1.18$1.18$1.29$1.183.60 million shs$35.11 million06/27/2025$1.30$1.30$1.34$1.23220,937 shs$38.68 million06/26/2025$1.29$1.30+0.78%$1.34$1.23220,937 shs$38.68 million06/25/2025$1.20$1.29+7.50%$1.31$1.20417,602 shs$38.38 million06/24/2025$1.21$1.20-0.83%$1.25$1.17252,025 shs$35.70 million06/23/2025$1.21$1.21$1.25$1.18189,507 shs$36 million Related Companies Voyager Therapeutics Stock Price Chart DiaMedica Therapeutics Stock Price Chart Black Diamond Therapeutics Stock Price Chart Galectin Therapeutics Stock Price Chart Innate Pharma Stock Price Chart SELLAS Life Sciences Group Stock Price Chart Aclaris Therapeutics Stock Price Chart I-Mab Stock Price Chart Instil Bio Stock Price Chart Puma Biotechnology Stock Price Chart Receive ELYM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ELYM) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
